JAK2 and ovarian carcinoma: Inhibitor of JAK, thus inhibiting the JAK/STAT pathway. Synergic effects of combined therapy on tumor growth in mouse model of advanced/ascites+ ovarian cancerJAK2 inhibitor that induced cytotoxicity in spire-forming CD24+ cells, thus inhibiting migration and metastasis of ovarian cancer in murine modelCombination of JAK2 inhibitor with chemotherapy inhibited paclitaxel-mediated OCSC enrichment and reduced tumor burden in mouse xenograftsSelective small-molecule bromodomain inhibitor that inhibits JAK/STAT pathway. JQ1 resensitized ovarian cancer cells to platinum